publication date: Sep. 29, 2017

Lowy & Schiller at the Lasker Awards: The paradox of disease prevention, and how some scientists rise above their peers

Douglas Lowy and John Schiller received the 2017 Lasker-DeBakey Clinical Medical Research Award on Sept. 15 for research that led to development of the human papillomavirus vaccine.

Lowy, who is completing his stint as the NCI acting director, becomes the first sitting head of the institute—permanent or acting—to win the award, which is described as America’s Nobel Prize (The Cancer Letter, Sept. 8).

“When many people think about recent research achievements in cancer and other diseases, the focus is usually on advances in the treatment of established disease,” Lowy said at the award presentation event. “At the risk of oversimplification, I see disease prevention as containing an inherent paradox.”

Lowy and Schiller, deputy chief of the Laboratory of Cellular Oncology and head of the Neoplastic Disease Section at the NCI Center for Cancer Research, developed the vaccine against HPV infection—an infection which is responsible for more than a half million cases of invasive cancer throughout the world each year.

“In my estimation, the accumulation of technical and conceptual knowledge in a certain field can combine to make even paradigm shifting discoveries inevitable,” Schiller said at the award ceremony.

 

Lowy’s acceptance remarks follow:

Andy Warhol told me that I was going to get 15 minutes of fame. The Lasker … Continue reading Lowy & Schiller at the Lasker Awards: The paradox of disease prevention, and how some scientists rise above their peers

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.